ArticleMedical care2017
Patterns of Buprenorphine-Naloxone Treatment for Opioid Use Disorder in a Multistate Population.
Article in Medical care, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05299515 (Peer-Delivered Behavioral Activation Intervention to Improve Adherence to MT Among Low-Income, Minority Individuals With OUD), which is not on this map. Cited by 58 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Peer-Delivered Behavioral Activation Intervention to Improve Adherence to MT Among Low-Income, Minority Individuals With OUD
Who cites it
58 citing papers in PubMed, 1 synthesis or guideline pooled it, 84 citations in OpenAlex.
- Pooled it
- Mobile Medication Adherence Platform for Buprenorphine (MAP4BUP): A Phase I feasibility, usability and efficacy pilot randomized clinical trial.Drug and alcohol dependence · 2024Trial
- Medicaid Prior Authorization and Discontinuation of Buprenorphine.Journal of addiction medicine · 2026Article
- Subgroup identification of disparities in buprenorphine discontinuation in opioid-use disorder: A Virtual Twins machine learning approach using nationwide United States claims data, 2006-2022.PLOS mental health · 2026Article
- Article
- Association of state medicaid prescription cap policies with trajectories of buprenorphine use for opioid use disorder.Journal of substance use and addiction treatment · 2025Article
- Self-reported experiences and perspectives on using psychedelics to manage opioid use among participants of two Reddit communities.Addiction (Abingdon, England) · 2025Article
- Patient outcomes following buprenorphine treatment for opioid use disorder: A retrospective analysis of the influence of patient- and prescriber-level characteristics in Massachusetts, USA.Addiction (Abingdon, England) · 2025Observational
- Pain, Substance Use Disorders, Mental Health, and Buprenorphine Treatment among Patients With and Without HIV.AIDS and behavior · 2024Article
- Are gaps in rates of retention on buprenorphine for treatment of opioid use disorder closing among veterans across different races and ethnicities? A retrospective cohort study.Journal of substance use and addiction treatment · 2024Article
- Buprenorphine treatment and clinical outcomes under the opioid use disorder cascade of care.Drug and alcohol dependence · 2024Article
- Impact of Alternative Ways to Operationalize Buprenorphine Treatment Duration on Understanding Continuity of Care for Opioid Use Disorder.International journal of mental health and addiction · 2024Article
- Single cell transcriptomics reveals distinct transcriptional responses to oxycodone and buprenorphine by iPSC-derived brain organoids from patients with opioid use disorder.Molecular psychiatry · 2024Article
- Defining Discontinuation for Buprenorphine Treatment: Implications for Quality Measurement.The American journal of psychiatry · 2024Article
- Barriers to retention in medications for opioid use disorder treatment in real-world practice.Journal of substance use and addiction treatment · 2024Observational
- Association of medications for opioid use disorder with reduced risk of repeat opioid overdose in Medicaid: A cohort study.Journal of substance use and addiction treatment · 2024Article
- Telehealth Initiation of Buprenorphine for Opioid Use Disorder: Patient Characteristics and Outcomes.Journal of general internal medicine · 2024Article
- Increasing medication assisted treatment in rural primary care practice: a qualitative comparative analysis from IT MATTTRs Colorado.Frontiers in medicine · 2024Article
- Receipt and duration of buprenorphine treatment during pregnancy and postpartum periods in a national privately-insured cohort.Drug and alcohol dependence reports · 2023Article
- Retention in Telehealth Treatment for Opioid Use Disorder Among Rural Populations: A Retrospective Cohort Study.Telemedicine journal and e-health : the official journal of the American Telemedicine Association · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundBuprenorphine-naloxone treatment for opioid use disorder has rapidly expanded, yet little is known about treatment outcomes among patients in the general population.
objectiveTo examine predictors of treatment duration, dosage, and continuity in a diverse community setting. RESEARCH
designWe examined QuintilesIMS Real World Data, an all-payer, pharmacy claims database, to conduct an analysis of individuals age 18 years and above initiating buprenorphine-naloxone treatment between January 2010 and July 2012 in 11 states. We used logistic regression to assess treatment duration longer than 6 months. We used accelerated failure time models to assess risk of treatment discontinuation. We used ordinary least squares regression to assess mean daily dosage. For patients with ≥3 fills, we also used logistic regression to assess whether ;an individual had a medication possession ratio of <80% and/or gaps in treatment >14 days. Models adjusted for individual demographics, prescribing physician specialty, state, and county-level variables.
resultsOverall, 41% of individuals were retained in treatment for at least 6 months and the mean treatment length was 266 days. Compared with individuals who paid primarily for treatment with cash, adjusted odds of 6 month retention were significantly lower for individuals with primary payment from Medicaid fee-for-service, Medicare part D, and third-party commercial. There were substantial differences in 6-month retention across states with the lowest in Arizona and highest in New York. Low-possession ratios occurred for 30% of individuals and 26% experienced treatment episodes with gaps >14 days. Odds of low-possession and treatment gaps were largely similar across demographic groups and geographic areas.
conclusionsCurrent initiatives to improve access and quality of buprenorphine-naloxone treatment should examine geographic barriers as well as the potential role of insurance benefit design in restricting treatment length.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.